Shares of Affimed N.V. (NASDAQ:AFMD) traded at a new 52-week high today of $5.58. Approximately 192,000 shares have changed hands today, as compared to an average 30-day volume of 1.3 million shares.
Affimed N.V. (NASDAQ:AFMD) is currently priced 12.5% above its average consensus analyst price target of $4.87.
Affimed N.V. share prices have moved between a 52-week high of $5.58 and a 52-week low of $1.42 and are now trading 292% above that low price at $5.57 per share.
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies.
Receive IBN`s Technical Indicator Alerts
To stay connected with our complimentary IBN alerts, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer